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     The aryl hydrocarbon receptor (AhR) has been reported to interact with 
multiple signaling pathways during prostate development including the androgen 
receptor. AhR was overexpressed in LNCaP using PLNCX2 retrovirus vector containing 
AhR cDNA to determine if ectopic overexpression induces castrate resistant phenotype. 
The highly overexpressed AhR clone illustrated further increase in transcriptional and 
promotor activity for AhR and AR compared to the moderately overexpressed AhR clone 
and control. Western blot analysis showed more AhR, AR, cSrc, and pSrc protein 
expression in clones. AhR overexpression was found to induce several biological 
properties such as migration, invasion, proliferation, and promotion of G1 to S phase 
during the cell cycle. Bicalutamide treatment had no effect on AR transcriptional activity 
in either clone, proving resistance to anti-androgen therapy. Our results confirm that 
overexpression of AhR induces constitutive activity and stimulates androgen receptor 
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 The most commonly diagnosed non subcutaneous cancer among men in Europe 
and USA, and the second most common in men worldwide is prostate cancer. The rate of 
prostate cancer has increased during recent decades, making it a leading cause of 
mortality. These incidences also vary noticeably between populations [1]. Etiological 
agents of prostate cancer include sex, age, ethnicity, family history, genetic factors and 
lifestyle. However, mechanisms of carcinogenesis in the case of prostate cancer have not 
been fully elucidated [2]. 
                Prostate cancer (PCa) is first manifested as an androgen-dependent cancer that 
can be successfully treated with androgen deprivation therapy (ADT). Androgen 
deprivation therapy causes a temporary reduction in PCa tumor burden, but the tumor 
eventually develops into castration-resistant prostate cancer (CRPC) with the ability to 
grow again in the absence of androgens [3]. Mechanisms of CRPC progression include 
androgen receptor (AR) amplification and overexpression, AR gene rearrangement 
promoting synthesis of constitutively-active truncated AR splice variants (AR-Vs) [4], 
and induction of intracrine androgen metabolic enzymes [3].  
            The AR, a steroid hormone receptor, is responsible for mediating the effects of 
the hypothalamo-pituitary-gonadal axis on prostate growth and function. Cytoplasmic AR 




        The AR is a ligand-activated transcription factor that promotes prostate cancer 
growth through genomic and nongenomic actions. In the canonical genomic pathway, the 
AR regulates transcription following interaction with specific DNA sequences, termed 
androgen response elements (ARE), in the regulatory regions of target genes [6]. More 
recently, it has been demonstrated that cytoplasmic AR, within minutes of activation, also 
stimulates kinase signaling cascades (e.g. ERK and PI3K) and this nongenomic signaling 
is also important in proliferation [6]. 
          In prostate and other tissues, aryl hydrocarbon receptor (AhR) signaling influences 
androgen signaling directly and indirectly. AhR is an evolutionarily conserved ligand 
activated transcription factor best known for its role in mediating toxic responses to 
dioxin-like environmental contaminants. However, AhR signaling has also emerged as an 
active participant in processes of normal development and disease progression [8]. In its 
inactive non-ligand bound state, the AhR is sequestered in cytoplasm by numerous 
protein complexes containing heat shock protein 90, prostaglandin E synthase 3, Src 
kinase, and AhR interacting protein [9]. Upon ligand binding, the AhR undergoes nuclear 
translocation and binds to ARNT. The AhR/ARNT heterodimeric receptor complex is 
recruited to AhR response elements (AhREs) in or nearby target genes. DNA binding by 
the AhR/ARNT heterodimer elicits context-dependent transcriptional transactivation or 
repression [10]. The most prominent members of the AhR-activated gene battery are drug 
metabolizing enzymes and some of which, including cytochrome P450 (CYP)1A1, 
CYP1B1, epoxide hydrolase, and glutathione S transferase mu 1, are present in human 




        AhR has role in the toxic effects caused by some environmental contaminants, 
including dioxins, polychlorinated biphenyls, and polyaromatic hydrocarbons. Recent 
evidence suggests AhR contributes to multiple cellular processes, such as the cell cycle, 
epithelial barrier function, cell migration, and immune function [12]. We have recently 
described another form of active AhR which is exogenous ligand independent. For 
example, it can be activated with endogenous ligand such as elevated cyclic adenosine 
monophosphate (cAMP) [13]. Moreover, one possible mechanism in cells that they have 
high levels of AhR, such as many tumor cell lines, is dynamic nucleocytoplasmic 
shuttling which helps AhR translocate to the nucleus, subsequently causing AhR and 
ARNT heterodimerization in the absence of ligand [14]. Overexpression of AhR was 
detected in various tumors including prostate cancer tissues, especially in malignant 
phenotype [15]. Lately, our lab found that the nuclear localization of the AhR in prostate 
cancer cells indicates its constitutive activation, although the exact molecular 
mechanisms leading to such activation remain indefinable [16]. 
         Some studies revealed that c-Src protein kinase is associated specifically with the 
AhR complex along with hsp90 in the cytosol and that upon ligand binding to the Ah-
receptor subunit, c-Src is activated and released from the complex [17]. In the Src family 
kinases (SFKs), there are nine structurally similar non-receptor protein tyrosine kinases. 
Intramolecular and intermolecular interactions can facilitate the activity of the SFKs. 
Phosphorylation of tyrosine residue (Y530), which is located at the carboxy terminal tail, 
has an important role in negative regulation for Src. C-terminal Src kinase (Csk) and Csk 




phosphorylation, we can observe the inactive form of Src with low enzymatic activity 
[22]. On the other hand, the increased Src activity is mainly due to the phosphorylation of 
Tyr-419. This activated form of Src has a principal role in mediating AR signaling [19]. 
This role can be phosphorylation of tyrosine (direct interaction) or serine/threonine 
(indirect interaction). Growth factors (IGF-1 and EGF), neuropeptides (GRP and 
bombesin), and interleukins (IL-6 and IL-8) are examples of molecules engaged in 
ligand-independent phosphorylation of AR [20, 21]. In the pathways mentioned above, 
activated Src is a common signaling intermediate which can subsequently phosphorylates 
AR. An additional role for activated Src is repression of the interaction of co-repressors 
such as LCoR with AR via inhibition of co-repressor-receptor interaction, and mediates 
AR function in cell growth [22]. We don’t have strong evidence for the exact mechanism 
underlying Src-induced AR activation. It has been suggested that AR translocation, 
transactivation, and binding to target genes is promoted by Src-induced AR 
phosphorylation. Active SrcY527F can stimulate AR nuclear translocation in the absence 
of ligand while kinase-inactive Src mutant overexpression reduced AR transactivation 
ability. To treat prostate cancer, it is important to consider AR and Src crosstalk [23].  
            Because of its critical role in prostate cancer, Src is overexpressed in androgen-
independent prostate carcinoma C4-2 cells. C4-2 cells are derivatives of LNCaP cells and 
express functional endogenous AR; they can grow in an androgen-independent manner 
making them an excellent model representing transition of the initial androgen- 
dependent disease to an androgen-independent state [24]. Asim et al. found that the 




Src is increased in androgen-independent PCa cell lines PC3 (two fold), C4-2 (three fold) 
[21]. 
          In addition to Src overexpression in C4-2 cells, our lab showed AhR mRNA and 
protein expression is significantly higher in androgen independent C4-2 prostate cancer 
cell lines (three fold) compared to the less aggressive androgen sensitive LNCaP prostate 
cancer cell line. Also, we can see nuclear AhR expression in C4-2 cells without 
exogenous ligand activation. Conversely, the LNCaP cells are nearly devoid of AhR 
expression in the nucleus, indicating that nuclear expression is attained with androgen 
independent progression [25]. 
          Several studies have investigated the role of AhR in cancer [26], with clear 
inconsistencies between pro- and anti-tumorigenic activities evident when utilizing cell 
culture versus in vivo models of malignancy [27] ; however, the role of AhR in inducing 
a castrate resistant phenotype in prostate cancer have not been investigated. Additionally, 
various tumor types show both AhR high level expression relative to the parent cell type 
[28], and significant constitutive receptor activity which plays a significant role in 
sustained androgen receptor signaling and growth [29], though  mechanism for AhR and 
AR interaction in prostate cancer cells remain unknown. Therefore, we investigated the 
following aims: 
1. To determine if overexpression of AhR induces constitutive AhR signaling in 
LNCaP cells. 
2. To determine if constitutive AhR signaling enhances Src kinase activity to 









                                                            CHAPTER II 
LITERATURE REVIEW 
 
2.1 Prostate Gland 
       The prostate gland develops embryologically from the urogenital sinus (UGS) which 
is an endodermal structure. Determination, initiation or budding, branching 
morphogenesis, differentiation, and pubertal maturation are five distinct stages in the 
prostate developmental process. Prostate development occurs during the second and third 
trimester of pregnancy and is complete at the time of birth. Prostate gland development is 
a complex process that involves coordination of multiple signaling pathways including 
endocrine, paracrine, autocrine, and juxtacrine [30]. 
       Prostate gland is a walnut-shaped structure located behind the bladder that entirely 
encapsulates the prostatic urethra and ejaculatory ducts. It is surrounded by a thin 
fibromuscular stroma and contains a glandular element consisting of several secretory 
acini emptying into branching tubuloalveolar ducts. These secretions produced by the 
glandular parts then empty into the urethra. In the male reproductive system, it is noted to 
be the largest accessory organ and its weight in young adult is approximately 20 g (See 
Appendix Figure 1). Two-thirds of its total mass consists of fibromuscular stroma, while 





      There are two cell layers, luminal and basal epithelial, which are surrounded by 
stroma in the mature prostate gland [32]. Polarized, columnar cells, which are luminal 
epithelial cells, cover the prostate lumen whereas elongated basal cells serve as a barrier 
between the lumen and the stroma. Pathologists can distinguish between these cells due 
to different cellular markers. Low levels of AR are found in the basal epithelial cells [33, 
34]. A third cell type, located within the luminal and basal cells, are AR-negative, post-
mitotic, and they can secrete growth factors and neuropeptides which help luminal cell 
growth. These neuroendocrine cells are unique. Lastly, epithelial cell homeostasis and 
prostate cancer progression can be impacted by the stroma [36]. We have similarity 
between the cell markers of prostate cancer and luminal cells while we can’t see this 
similarity with basal cells. It can help to conclude that luminal cells are the alleged cell of 
prostate cancer origin.  
     Though presence of cell markers explains luminal cell as the prostate cancer origin, 
recent evidence indicates that both luminal and basal epithelial cells could be tumor 
initiating [32]. By injecting a mixture of murine urogenital sinus mesenchyme (UGSM) 
and prostate epithelial cells under the kidney capsule, researchers hope to answer the 
mechanism of prostate gland formation, prostate cancer cell of origin, and prostate cancer 
initiation. This tissue recombination allows them to develop a fully differentiated and 
functional prostate gland under physiologic androgen levels, and the ability to manipulate 
several molecules needed for prostate gland formation. Epithelial cells were origin of 
initiated cells and they were capable of repopulating prostatic lumen following ADT-





2.2 Benign prostatic hyperplasia & Prostate cancer 
         Prostate cancer progresses in the prostate gland and the tumor cells can spread from 
the prostate to other parts of the body, such as lymph nodes and bones. Common 
urogenital diseases in older men are benign prostatic hyperplasia (BPH) and prostate 
cancer. One out of five men with prostate cancer also has BPH, and cancer is found 
incidentally in a significant percentage (10%–20%) of surgically removed BPH 
specimens. In addition to coexistence, epidemiologic studies have also reported an 
association between BPH and prostate cancer [38]. 
       One reason for bladder outlet obstruction is urethral obstruction secondary to benign 
prostatic enlargement as a result of BPH. Symptoms of this include elevated bladder 
pressure and urethral resistance. Moreover, benign prostatic hyperplasia can cause 
difficulty in voiding the bladder due to over activity of the bladder detrusor base [39- 41]. 
After increasing the amount of stromal and epithelial cells, which happen first in the 
periurethral and transition zones of the gland, we can detect BPH. The role of smooth 
muscle in increasing the muscular tone of the hyperplasic prostate is more important than 
glandular epithelium in stromal hyperplasia (See Appendix Figure 2) [38]. 
       The second most frequently diagnosed cancer and the sixth leading cause of cancer 
death in males is prostate cancer [42]. This cancer has been known as a clinical entity 
since discovery, when it was first described by the ancient Egyptians, while surgical 
procedures to remove the prostate were developed more than 100 years ago [43].                                    




(PSA) also known as gamma-seminoprotein or kallikrein-3 (KLK3) testing (it has 
revolutionized the diagnosis of prostate cancer over the past three decades), digital rectal 
examination (DRE) and defined by histological examination of prostate core needle 
biopsies defining the degree of tumor malignancy by the Gleason score [44]. PSA is a 
kallikrein-related serine protease which is produced in normal prostate secretions, but is 
released into the blood as a result of interruption of normal prostate architecture [45]. 
      The most important risk factors for the development of cancer are advanced age, and 
family history. For prostate cancer, African American ancestry has a significant effect; 
however, there is also a definite environmental distribution to prostate cancer as obvious 
increase in risk with the incorrect lifestyle. Obviously, environmental factors has 
significant role in the pathogenesis of prostate cancer in addition to hereditary factors. 
Polyaromatic hydrocarbons, heterocyclic aromatic amines and dioxin-like compounds are 
environmental carcinogens shown to initiate cancer in a number of tissue types including 
prostate. Also, chronic inflammation in the prostate due to a number of potential causes 
including infections, dietary factors, hormonal changes are such potential environmental 
factors which have earned a great deal of recent attention for prostate cancer initiation 
and progression[46, 47]. As we mentioned before, primary origin of prostate cancer cells 
is believed to be luminal cells because of the absence of basal cells signs and luminal cell 
markers present in prostate cancer [48]. 
      We have some evidences for phases of the clinical progression pathway that are 
relevant issues for patient outcome. These phases are: A) detection of prognostic markers 




mechanisms that lead to androgen independence; C) understanding about prostate cancer 
metastasizes destinations; D) concentrating the mechanisms underlying prostate cancer 
initiate, progress and going to castrated resistant phenotype [49]. Originator of prostate 
carcinoma was determined by histopathological studies of prostate cancer tissue. The 
precise diagnosis of prostatic intraepithelial neoplasia (PIN) had historically created some 
argument and uncertainty in terms of its clinical significance and relationship to prostate 
cancer. Though, more recent studies verify that high-grade PIN (HGPIN) shares a 
clinical, morphological, and genetic background with prostate cancer [50]. While the 
primary classification of PIN included three different grades of dysplasia, currently, only 
HGPIN with increase in the size and number of foci has been associated with both 
prostate adenocarcinoma and its multifocality. HGPIN and carcinoma tend to 
preferentially involve the peripheral zone of the prostate [51, 52]. PIN association with an 
elevation in serum PSA levels is one of the concerning area. Some researchers showed 
that in men undergoing simple prostatectomy, the finding of PIN was associated with a 
high PSA level. On the other hand, Alexander and colleagues reported that PIN does not 
seem to increase PSA levels. Obviously, only formation of PIN without prostatic 
carcinoma can be reached with whole-mount step-sectioning of the prostate tissue, which 
may explain this inconsistency (See Appendix Figure 3) [53, 54]. 
2.3 Castration resistant prostate cancer 
        Huggins and Hodges described the dependence of prostate cancer cells on androgen 
stimulation for the first time [55]. After that, therapies directed toward suppressing 




disease. Androgen binds to the AR and translocate to the nucleus, where the binding of 
this complex to Androgen Responsive Elements affects the transcription of androgen-
regulated genes (e.g. prostate-specific antigen, PSA) and eventually promotes 
proliferation and inhibits apoptosis of prostate cancer cells [56]. 
        For early metastatic prostate cancer, androgen-deprivation therapy by chemical and 
surgical castration has been the backbone of the treatment. Over a period of 18–20 
months, hormonal suppression for metastatic prostate cancer fails to effect durable 
complete remissions, with the predictable emergence of progressive disease that is 
variously termed hormone independent, hormone refractory, or castration resistant 
prostate cancer (CRPC). The average survival in the setting of castration-resistant 
metastasis is between 1–2 years [57]. 
       For the development of CRPC, based on androgen-regulated genes role in ‘hormone-
refractory/castration-adapted’ prostate cancer, several molecular mechanisms have been 
defined the processes that contribute to androgen receptor activation in the castrate 
environment. Suggested mechanisms include: A) Prostate cancer cells become 
“hypersensitive” to androgen stimulation by amplification/over-expression of the AR. 
Consequently, we can see progression of the disease to the bone, B) AR gene mutations 
leading to immoral ligand or cofactor interaction, C) enhanced AR signal transduction 
through alterations in coactivators/corepressors, and D) autocrine and paracrine 
production of androgens can be upregulated. The AR may be activated in this setting by 
steroids other than androgens such as estrogens, and ligand-independent activation of the 




downstream regulatory molecules by “cross talk” with other signaling pathways (See 
Appendix Figure 4). Bypass pathways have been identified as contributor to AR 
independent growth of prostate cancer cells, such as interleukin-6 signaling and Her2 
[58-60].  
       Studies of these processes characterize valuable insight of investigation as they each 
may provide an explanation for a component of what is viewed as androgen-independent 
disease. Though there naturally may be pathways leading to prostate cancer growth, and 
AR signaling, that are completely ligand-independent, many of the mechanisms classified 
so far still require or are enhanced by the presence of ligand. Therefore, the most 
straightforward reason for persistent/recurrent AR signaling is the persistence of 
androgenic ligands at levels adequate to engage a wild-type AR [61, 62]. 
2.4 Androgen Receptor 
2.4.1 AR structure and activity 
         One member of the steroid hormone receptor family is androgen receptor (AR) and 
it shares a similar domain organization with other members of the nuclear receptor (NR) 
which is primarily responsible for mediating the physiological effects of androgens by 
binding to specific DNA sequences, known as androgen response elements (AREs) [63]. 
In the lack of androgens, AR normally is localized to the cytosol in a complex with 
molecular chaperones, Hsp40, 70 and 90 in an inactive form. Upon androgen binding, the 
AR induces conformational changes in the AR protein, the AR forms a dimer, which 
translocate from the cytoplasm to the nucleus [64]. The nuclear translocation of AR 




transcription factor. AR, signaling plays a critical role in prostate cancer cell 
proliferation, survival, and differentiation [65]. 
       The AR gene is placed on the X-chromosome at position Xq11-12 and is 183 
kilobases in length. It contains eight exons which are separated by comparatively long 
introns. The AR protein has 919 amino acids and its molecular weight is 110 kDa, based 
on NCBI AR reference sequence NM_00044.2. The full-length AR protein is 
polymorphic as a result of variable-length stretches of polyglutamines and polyglycones 
within the NH2-terminal domain (NTD). AR exon 1 encodes the complete AR NTD, 
which includes about 60% of the AR protein, and each encode one zinc finger of the AR 
DNA binding domain (DBD) is produced by exons 2 and 3. The AR hinge region is 
encoded by the 5′ portion of exon 4, and the remaining exons 4-8 encode the AR ligand 
binding domain (LBD) and transcriptional activation function-2 (AF-2) domain [66]. AR 
has two activation function (AF) motifs, AF1 in the NTD and AF2 in the LBD. However, 
unlike other nuclear receptors where AF2 has strong transcriptional activity, AF1 is 
responsible for the majority of AR activity. In androgen-dependent PCa cells, the activity 
of the full-length AR depends on ligand binding c [67]. 
2.4.2 AR regulation in normal prostate gland 
      During embryo phase the initial cell determination step for development of the male 
reproductive tract happens, but terminal cell differentiation occurs through sexual 
maturation [68]. The prostate gland is the part of the male reproductive system that 
makes the majority of seminal fluid. Prostate tissue develops from the urogenital sinus, 




mesenchyme, the outer layer of embryonic connective tissue surrounding the urogenital 
sinus epithelium [69]. Androgenic steroids are 19-carbon steroids of which, testosterone 
is the prototype. It is produced primarily by the testes in males with a small contribution 
from the adrenal glands [70]. 
    To transform adult bladder epithelium or bladder stem cells into prostatic glands, AR 
expression in urogenital sinus mesenchyme is sufficient. A similar tissue signaling 
relationship occurs in normal adult prostate, in which stromal AR is an essential regulator 
of epithelial cell proliferation, survival and differentiation. On the other hand, AR 
expressed in normal prostate epithelial cells is mainly responsible for regulating genes 
required for synthesis of proteins that are secreted into the prostate lumen and 
interestingly, Androgens play a role in a wide range of developmental and physiological 
responses [71]. In the normal prostate, the predominant role of AR is to promote 
differentiation of luminal epithelial cells and to regulate the transcription of genes 
encoding proteins necessary for prostate function, such as prostate specific antigen (PSA) 
[72]. 
2.4.3 AR and prostate cancer  
    Both normal and prostate cancer cells need androgens in order to live and develop. The 
rate of cell proliferation to the dead cell rate is an accurate index for measuring the 
growth of all cells including prostate cancer cells [73]. Androgens and the androgen 
receptor are the major regulators for this ratio in the prostate. The order of this ratio will 
change in all cancers, including prostate cancer, as we have more proliferated cells and 




      Many studies are based on molecular cloning of AR cDNA from human and mouse, 
which provides strong support that AR transcriptional activity is critical for all stages of 
prostate cancer development and progression. Certainly, several neutral next-generation 
sequencing platforms have been used to characterize PCa at the genomic level, and 
results have constantly approved a critical role for activity of the androgen/AR axis [74]. 
       Based upon the importance of AR pathway in prostate cancer, androgen suppression 
therapy is the main choice of treatment. GnRH (gonadotropin-releasing hormone) such as 
leuprolide and goserelin (considered as a chemical therapy) or orchiectomy (considered 
as a surgical therapy) are the first line of treatment for prostate cancer. With these two 
castration methods, we can suppress androgen [75]. Following this step, patients undergo 
androgen deprivation therapy. In order to reach total androgen suppression, patients are 
given leuprolide and nonsteroidal antiandrogens (flutamide, bicalutamide, and 
nilutamide). Oral usage of these drugs is used usually to block androgens [76, 77]. The 
significant functions of AR are less clear in prostate cancer, while probably AR activity 
modulates the expression of genes associated with cell cycle regulation, survival and 
growth [78]. Additionally, whole genome sequencing analysis of 11 early onset prostate 
cancers suggested that androgens, through the AR, likely contribute in shaping the 
somatic alternation [79]. Furthermore, this is supported by studies demonstrating that AR 
is known to stimulate the expression of TMPRSS2: ERG, a common gene fusion 
associated with PCa initiation via androgen-driven overexpression of the gene fusion 




          Despite most cancer patients with androgen deprivation therapy remaining in 
remission for a long period of time, developing a castration-resistant form of the disease 
is unavoidable [81, 82]. Because this lethal type of prostate cancer does not respond to 
the first-line of treatment anymore, the next line of treatment must be prescribed.  The 
anti-mitotic compound, docetaxel, has been given to help CRPC patients. This choice of 
chemotherapy can help the patient increase their lifespan [83, 84]. There are several 
known mechanisms for developing castration resistance; however, the exact mechanism 
is not well understood.  
       Overexpressed AR in the cell is the first underlying mechanism of CRPC. AR gene 
amplification is one reason for AR overexpression which can explain one-fourth of 
androgen-insensitive tumor development after androgen deprivation therapy [85]. Based 
on this mechanism, we cannot conclude that the cells are actually independent to the 
androgen. Because the androgen receptor is overexpressed here, the cell can respond to 
the low levels of androgen. This means they are more sensitive to androgens and can 
increase the number of the cells in the starved environment [86]. 
     Ligand promiscuity is the second mechanism in developing castration resistant 
prostate cancer. Mutations in the AR gene are the reason for this promiscuity. In the AR 
ligand binding domain, we can see substitutions of some amino acids (e.g., T877A, 
L701H, W741L, and F876L) which can decrease specificity. This mutated domain will 
not select a ligand and it can bind to other steroid hormones (progesterone, estrogen, and 
glucocorticoids). This alternative ligand can induce AR transcriptional activity and 




described before, flutamide is one of our choices of treatment as an antagonist. 
Interestingly, after some AR mutation (T877A), this drug can act as an agonist and 
induce prostate growth [88]. 
        Androgen receptor can be independent to ligand for its activation. This is the next 
mechanism that can explain CRPC development [89]. Epidermal growth factor (EGF), 
insulin-like growth-factor-1 (IGF-1), and keratinocyte growth factor (KGF) as ‘outlaw 
receptor’ are some examples of the tyrosine kinase receptor-activating ligands and can 
induce AR activation after activating the downstream PI3K/AKT/mTOR pathway [90]. 
Src non-receptor tyrosine kinases and Ack1 are examples of signaling pathways which 
can crosstalk with the androgen receptor and activate it [91- 95]. NH2-terminal domain is 
regulated by AR. In some point, lack of the LBD in some AR variants can play as 
negative regulators for NTD. In this case, without LBD, AR NTD can be constitutively 
active and make castration resistant prostate cancer [96, 97]. 
        Bypassing AR signaling is the last pathway we want to describe here as a reason to 
develop CRPC. After castration therapy in mice prostate, dying prostate cancer cells 
activate an inflammatory response. As a consequence of that, infiltration of B and T cells 
was detected. Stat3 signaling was motivated due to infiltrating B cells which made 
lymphotoxin and factors. With this Stat3 signaling activation, we can see prostate cancer 
cell growth in a hormone-free environment [98]. We have similar mechanisms for 
upregulated anti-apoptotic protein Bcl-2 which keeps cancer cells alive after castration 
therapy that induces apoptosis [99].  Overexpression of gonadotrophin receptor is a 




gonadotrophin overexpression which are essential for prostate cancer cell growth [100]. 
These aforementioned pathways may increase AR signaling pathway activity 
concurrently.  
        Regardless of the mechanism, it is clear that AR signaling plays a critical role in the 
development and progression of PCa and, re-activation of the androgen/AR signaling axis 
is a central component of progression to CRPC. 
2.4.4 Tyrosine Phosphorylation of AR 
            AR totally has at least sixteen phosphorylated residues recognized up to now. 
Several of them are phosphorylated after treatment of cells with androgen (testosterone or 
dihydrotestosterone [DHT]), antiandrogen, or reagents which activate other signaling 
pathways and alter transcriptional activity, cellular localization, and stability of AR [101]. 
This phosphoprotein has several serine/ threonine and tyrosine residues that are 
phosphorylated. Most of the phosphorylated residues are located in NTD that regulate 
AR cellular localization, stability and its transcriptional activity. 
       Recently, several groups have reported that tyrosine phosphorylation of AR protein 
by non-receptor tyrosine kinases Src may have a role in AR activation in the low 
androgen environment, thereby promoting the development of CRPC. Src-mediated 
phosphorylation of AR at Y534 resulted in the activation of AR and nuclear translocation 







2.5 Aryl Hydrocarbon Receptor (AhR) 
2.5.1 AhR structure 
        The AhR is a member of the family of basic helix-loop-helix/Per-ARNT-Sim 
(bHLH-PAS) transcription factors. The mammalian AhR protein contains four major 
structural motifs and is approximately 90 kDa. The first is an N-terminal basic-helix-
loop-helix DNA binding domain, the second is a transactivation domain, and the third 
and fourth are protein-protein interaction and ligand binding PAS domains, named after 
their homology with the clock protein period (Per), the xenobiotic and oxygen sensing 
protein aryl hydrocarbon receptor nuclear translocator (ARNT), and the neuronal cell 
lineage regulator single-minded (Sim). The AhR is one of at least 34 known mammalian 
PAS family members and is evolutionarily conserved in species ranging from flies to 
humans (See Appendix Figure 6) [105]. The aryl hydrocarbon locus, which contains 
AhR, AhR nuclear translocator and AhR repressor (AHRR), was first identified in 1972 
[106].  
2.5.2 Mechanisms of AhR activation 
2.5.2.1 AhR agonists 
           AhR can bind to different chemicals in its ligand dependent manner. These 
chemicals can increase AhR activity. Some studies show that 2,3,7,8-tetrachlorodibenzo-
p-dioxin (TCDD) and components of cigarette smoke, like benzo(a)pyrene (BaP), and 
PAH compounds, exert their biological influences by binding directly to a cytosolic 
receptor, now known as the AhR. AhR is induced by PAHs and its primary role is the 




        The AhR is a transcription factor (ligand-activated dependent or constitutively 
active). It binds to ARNT protein after translocation to the nucleus. This heterodimer 
complex induces some gene expression within direct interaction with dioxin responsive 
elements (DREs) (See Appendix Figure 7) [108]. AhR has an important role in cellular 
maintenance and disease formation. Based on high expressions of AhR in different parts 
of the body, we are interested in determining its exact functionality. RNA interference, 
overexpression, and inhibition studies implicate the AhR’s role in different types of 
cancer cell initiation and tumor progression in animal models [109]. 
      By measuring AhR transcriptional activity via different assay systems, it has been 
determined that AhR can be activated by chemical reagents, fruit, vegetables, and 
seasonings and that this could significantly affect the total amount of AhR ligand 
exposure [110, 111].  Further investigation showed numerous drugs that exhibit off-target 
activity through binding to the AhR [112]. Additionally, a number of reports have 
classified certain dietary ingredients that are AhR ligands. Flavonoids (e.g. quercetin, 
apigenin, kaempferol) which show AhR agonist and antagonist activity (depend to cell 
line) is one example of dietary [113, 114]. Furthermore, indole glucosinolates which are 
found in cruciferous vegetables, upon consumption, are broken down to indole-3-
carbinol. Indole-3-carbinol then undertakes condensation reactions in the stomach (acidic 
environment), making numerous products that are able to activate the AhR, with the 
compound of highest affinity for the AhR being indolo [3, 2 b] carbazole [115]. 
       We can conclude AhR has a significant role in the response to microflora when we 




metabolize tryptophan to indole, indole-3-acetate and indole-3-aldehyde which are AhR 
ligands [116, 117].  
2.5.2.2 Ligand independent activation 
        AhR can be active without binding to exogenous ligand. One example of this 
exogenous ligand independency is the apparent ability of elevated cAMP levels to 
activate the AhR [118]. Moreover, it is probable that in cells that have comparatively 
high AhR levels, such as many tumor cell lines, the AhR undergoes dynamic 
nucleocytoplasmic shuttling, which could lead to AhR and ARNT heterodimerization in 
the absence of ligand [119]. Support for this idea can be obtained upon comparing the 
level of retained nuclear AhR in a human head and neck squamous cell carcinoma cell 
line, NH30, compared to normal human keratinocytes [120]. Nevertheless, the presence 
of AhR ligands in these squamous cell carcinoma cells cannot be ruled out. Shear stress 
in endothelial cells can also lead to AhR activation, although the mechanism of activation 
is not known [121, 122]. Co-expression of a mutant AhR unable to bind ligand (AhR-
A375I) and ARNT increased AhR-mediated transcriptional activity suggests that the AhR 
can potentially heterodimerize with ARNT in the absence of ligand, although 
heterodimerization potential appears to be quite inefficient [123]. 
2.5.3 Role of AhR signaling in prostate development 
      Despite the fact that the expression level of AhR in different organs is variable, AhR 
is detected in most tissues. The liver, lung, spleen, and kidney are noted to have the 
highest levels of AhR, whereas skeletal muscle lacks AhR completely. In all tissues we 




instance, breast, prostate, gastric, small cell lung, and liver tumors immunohistochemical 
analysis exhibit increased levels of AhR expression relative to surrounding tissue [124, 
126]. Almost all knowledge of AhR signaling during prostate development has been 
obtained from the laboratory rodent.  The growth of AhR −/− mice has proved that the 
role of this receptor is not just the facilitation of the effects of HAs and PAHs [127]. 
Decreased liver size, decreased fertility, and functional and structural deficits in several 
tissues was the effect of AhR depletion in those mice [128] and these involved in 
decreased levels of mature follicles and uric acid stone formation in the urinary bladder 
[129]. Furthermore, AhR −/− mice show abnormalities in stem cells and their function 
[130]. 
       Through all stages of male urogenital system development, the main parts of the 
AhR signaling pathway, AhR and ARNT, are likely to be found in prostate. AhR and 
ARNT genes are expressed in fetal mouse and rat urogenital sinus and in normal, 
hyperplastic, and cancerous adult human prostate [131]. In mice, AhR deletion does not 
alter prostatic budding and branching morphogenesis, while anterior and dorsolateral 
prostate weights are faintly decreased [132]. AhR ectopic activation by TCDD is 
adequate to disrupt key stages of ductal morphogenesis while AhR is not necessary for 
prostate development. TCDD-induced AhR activation during fetal-pubertal development 
significantly delays prostate growth as assessed by decreased relative prostate lobe 
weights in rats and mice [133] and decreased number of lumenized prostate ducts in 




    The mechanism of AhR action in prostate development is functionally involved in 
other signaling pathways. 
2.5.4 Crosstalk between AhR and AR signaling 
        In prostate and other tissues, AhR signaling influences androgen signaling directly at 
the level of AR and indirectly through actions on the endocrine system [105]. AhR plays 
a significant role in sustained androgen receptor signaling and growth [25]. But, the 
mechanism for this role is not clear yet. First possible mechanism is direct interaction 
between AhR with AR. AhR has been reported to directly interact with a number of 
nuclear proteins [25].This direct heterodimerization can occur in the cell and explain the 
crosstalk between AhR and AR. Additionally, interaction can happen via coactivators. 
AhR and androgen receptor sometimes share a number of coactivator proteins such as 
SRC1 and p300 [135].  The other possible mechanism AhR can use for androgen receptor 
activation is phosphorylation of the receptor with Src kinase [136]. Src was shown to 
mediate crosstalk between AhR and epidermal growth factor receptor in colon cancer 
cells [137]. The other studies have shown that Src kinase can cause androgen receptor 
transactivation in C4-2 cells. Inhibition of Src kinase function with a specific inhibitor 
resulted in decreased androgen receptor activation [21]. Coimmunoprecipitation 
experiments revealed that AhR forms a protein complex with Src and regulates Src 
activity by phosphorylating Src (Tyr416) and dephosphorylating Src (Tyr527) [17]. 
Immunoprecipitation assays revealed the association of AR with Src, suggesting complex 




      Therefore, the precise molecular mechanism utilized by constitutive AhR signaling to 
activate androgen receptor signaling needs to be investigated further and could include 
induced activation via protein phosphorylation, direct heterodimerization and interacting 
via coactivators [25]. 
2.6 Src family kinases (SFKs) 
2.6.1 SFKs structure 
       Src, Fyn, Lyn, Yes, Blk, Lck, Hck, Fgr, and Yrk are nine structurally similar non-
receptor protein tyrosine kinases that belong to the Src family kinases (SFKs) [139]. Four 
Src homology (SH) domains, distinct peptide domains, form SFKs’ amino acid 
composition and consist of a conserved arrangement, as well as a regulatory sequence 
[140]. First domain is the SH4 domain which is followed by unique region that is similar 
to each family member. After that, we have the SH3 and SH2 domains which facilitate 
the association and interaction with adaptor and signaling proteins engaged in the 
development of complexes. This is done by the SH3 domain leading Src complexes with 
proline-rich and other hydrophobic amino acids [141- 143]. A polyproline type II helix 
will form after protein-protein interactions through the association of the hydrophobic 
sequence of SH3 domain. The SH2 domain has high affinity for phosphotyrosine-
containing sequences (pTyr-Glu-Glu-Ile) [144]. Connection of SH2 and peptides creates 
a two-pronged plug (peptide) engaging a two-“holed” socket (SH2). The first “hole” is 
occupied by phosphotyrosine, while isoleucine is located in the second SH2 “hole”. 
Regulation of the kinase activity is another SH2 and SH3 domains role. This regulation 




interactions of individual SFKs. The SH1 domain houses the intrinsic tyrosine kinase 
activity of the molecule and is followed by a carboxy terminal regulatory domain (See 
Appendix   Figure 8) [145]. 
2.6.2 Src Activation in Cancer 
      Differentiation, cell morphology, proliferation, migration, invasion, adhesion, and 
survival are some examples of Src actions on mammalian cells. Src kinase activation is 
common in various types of cancers. Accordingly, upstream kinases or phosphatases 
mediated Src activity by structural modification. Intramolecular interactions and 
localizations are some ways that can regulate SFKs activities. The net phosphorylation 
status of Src at its regulatory residues determines the activation status of Src, which is 
dependent upon a balance between phosphatase and kinase enzymes [146]. The Src-
family tyrosine kinases are oncogenic enzymes that contribute to the initiation and 
progression of many types of cancer. In normal cells, SFKs are kept in an inactive state 
mainly by phosphorylation of a consensus regulatory tyrosine near the C-terminus (Y 530 
in the SFK c-Src) [147]. c-Src protein kinase is associated specifically with the AhR 
complex along with hsp90 in the cytosol and that upon ligand binding to the Ah-receptor 
subunit, c-Src is activated and released from the complex [17].  
   Src plays an important role in cell proliferation, differentiation, adhesion, and 
migration. The increased Src activity is mainly due to the phosphorylation of Tyr-419, 






2.6.3 Expression of SFKs in prostate cancer 
      The role of Src and other SFKs in prostate cancer initiation and progression has been 
found by the level of its expression in prostate cells [149]. Growth factors like EGF, IGF-
1, VEGF, cytokines such as Il-8, reactive oxygen species, neuroendocrine ligands, or 
even intracellular activating proteins such as FAK are stimuli that can regulate SFKs 
activity in prostate cancer cells. The abnormal SFKs activity, which is regulated by the 
above molecules, can change many basic aspects of cancer progression, including cell 
proliferation, adhesion, migration, and invasion. SFKs can thus be considered as essential 
components of the signal transduction pathways participating in proliferation, normal 
cellular growth, migration, and survival, all of which are processes that, if altered, 
promote tumor progression [150]. 
       Src and AhR coexist in a protein complex that also likely contains heat-shock protein 
90, AhR-interacting protein, and P23. TCDD-AhR interaction results in time- and dose-
dependent phosphorylation of Src (Tyr416). Src-mediated cross talk between AhR and 
EGFR signaling pathways provides an important link between AhR canonical function 
and TCDD-mediated tumor promotion [17]. 
       Src is able to phosphorylate the AR via direct physical interaction with the AR, and 
so stimulate ligand-independent AR activation (one of the key mechanisms of castration-
resistant prostate cancer). Src is a potent and specific therapeutic target for CRPC 
progression. Following Src phosphorylation of AR, changes in molecular processes 
occur, which include decreased proteasomal degradation, increased AR translocation to 




result is the activation of AR-dependent gene expression programs [151]. On the other 
hand, wild-type Src for its oncogenic potential is dependent on AR overexpression. This 
implies that Src can be activated by AR. Actually, cross-activation between the AR and 
Src is obviously suggested as a way to elucidate their synergy, which is possibly favored 
by a physical interaction between both proteins. Moreover, both protein have a proline-
rich zone which is located on SH3 domain for Src. AR-Src complex can form based on 
this proline-rich zone (See Appendix Figure 10) [152]. 
2.7. AhR expression and activity 
2.7.1 AhR expression in androgen sensitive and castration resistant prostate cancer 
cell lines 
       LNCaP is androgen sensitive and C4-2 is castration resistant prostate cancer cell 
lines, which are appropriate as a model system because the pair serve as an in vitro model 
of prostate cancer progression from hormone sensitive to hormone refractory. The 
castration resistant C4-2 cells were derived from a chimeric tumor induced by inoculating 
a castrated mouse with parental androgen sensitive LNCaP cells [153]. Our lab 
performed extensive studies for comparing AhR mRNA and protein expression in the 
LNCaP cells to the C4-2 prostate cancer cell line, which revealed that AhR mRNA 
expression was increased in C4-2 cells by 3-fold (See Appendix Figure 11A and B). 
Subsequently, protein expression was also revealed to be increased 3-fold by 






2.7.2 Aberrant AhR Transcriptional Activity in C4-2 Cells 
     With immunocytochemical staining, we revealed enhanced nuclear localization of 
AhR protein in C4-2 cells while remaining cytosolic in androgen sensitive LNCaP cells 
(See Appendix Figure 12A). Also, the researchers found AhR is expressed in the nucleus 
of C4-2 cells without exogenous ligand activation. The LNCaP cells are virtually devoid 
of AhR expression in the nucleus, indicating that nuclear expression is acquired with 
androgen independent progression (See Appendix Figure 12B). Further evidence that 
AhR is constitutively active in C4-2 cells is provided by the expression of AhR 
responsive genes under normal cell culture conditions and in the absence of exogenous 
ligands. CYP1B1 is expressed in C4-2 cells but require activation with TCDD to be 
expressed in LNCaP cells (See Appendix Figure 12C and D). 
2.7.3 Depletion of AhR reduces AR activity 
       Regardless of the molecular mechanisms involved, the AhR has a significant effect 
on androgen receptor. C4-2(-AhR) cells established by depletion of AhR protein in C4-
2(-AhR) cells, then our lab showed the effect of AhR expression and signaling on AR 
expression and signaling. Immunocytochemical staining revealed that depletion of AhR 
protein in C4-2(-AhR) cells resulted in reduced nuclear localization of AR (See Appendix 
Figure 13A). Additionally, subcellular fractions revealed an 80% decrease in AR protein 
expression in the nucleus while there was not a significant decrease in cytoplasmic AR 
expression (See Appendix Figure 13B and C). Western blot analysis confirmed an 80% 
decrease in p AR, which is the active form of AR. Furthermore, C4-2 (-AhR) cells also 




and KLK3 (Kallikrein-Related Peptidase 3) (See Appendix Figure 13D and E). These 







Investigate the molecular mechanisms of Crosstalk between AhR and AR 
       Previous studies have shown that AhR plays a significant role in sustained androgen 
receptor signaling and growth. However, role of AhR in the development of CRPC has 
not been elucidated and it needs the focus of intense investigation. There are numerous 
possible mechanisms for AhR and AR interaction.  For example AhR and androgen 
receptor share a number of coactivator proteins such as SRC1 and p300; therefore, their 
interaction can happen via these coactivators [135]. The other possible mechanism is 
direct interaction between AhR and AR [25]. In addition AR has been shown to be 
activated by Src kinase mediates phosphorylation [21]. Activation of AhR enhances Src 
kinase activity and may serve as a mechanism of cross talk between AhR and AR 
signaling pathways. 
        We investigated the effect of AhR and Src signaling on androgen receptor function 





(CH223191) and Src kinase inhibitor, 4-amino-5-(4-chlorophenyl)-7-(t-
butyl)pyrazolo[3,4-d]pyramidine (PP2). We also, investigated the effect of these 
treatments on C4-2 cells in our lab.  
Co-inhibition of AhR and Src abolishes phosphorylation of AR 
         Protein samples were isolated using the commercially available cell lysis buffer 
(Cell Signaling) for total protein and western blot analysis was used to determine protein 
expression of AhR, AR, pAR, cSrc and pSrc. 
    We previously reported decreased pAR in C4-2 cells with shRNA mediated reduction 
in AhR protein expression. Here, western blot analysis reveals a corresponding decrease 
in pSrc expression (See Appendix Figure 14) [25, 154]. In order to determine the effects 
of chemical inhibition of AhR and Src, C4-2 cells were treated with 4-amino-5-(4-
chlorophenyl)-7 (dimethylethyl) pyrazolo [3,4d] pyrimidine (PP2) and specific AhR 
inhibitor (CH223191). PP2 is a widely used compound to block the activity of Src family 
kinases, reduced phosphorylation of Src and AR in C4-2 cells [155]. The addition of 
specific AhR antagonist CH223191 abolished both Src and AR phosphorylation in the 
presence of PP2. The expression levels of non-phosphorylated AR and Src were not 
affected with treatment (See Appendix Figure 15). 
Nuclear AR is AhR / Src dependent 
      The translocation of AR into the nucleus is dependent upon the phosphorylation of 
AR. In order to address the role of AhR and Src in this process cellular fraction were 
analyzed for AhR expression by western blot to determine sub-cellular localization. 




greater effect seen with PP2. However, simultaneous inhibition of AhR and Src abolished 
AR nuclear localization (See Appendix Figure 16). 
Co-inhibition of AhR and Src decreases promoter activity of AhR and AR 
      The Cignal XRE and ARE luciferase reporter assays were utilized to determine the 
activity of AhR and AR signaling pathways in androgen independent (C4-2) prostate 
cancer cells in the presence and absence of inhibitors. The assay showed that C4-2 
prostate cancer cells have a high level of AhR and AR promoter activity in the absence of 
inhibitor treatment. CH223191 reduced AhR promoter activity by 30% while PP2 
resulted in a 50% decrease in promoter activity compared to DMSO. Both CH223191 and 
PP2 reduced AR promoter activity by 70% compared to the DMSO treated cells. 
Simultaneous inhibition of AhR and Src in C4-2 cells with CH223191/PP2 resulted in 
minimal AR promoter activity. Co-treatment with CH223191 and PP2 significantly 
decreased AR promoter activity compared to CH223191 or PP2 alone (See Appendix 
Figure 17). 
Synergistic inhibition of AhR and AR target gene expression 
        To confirm the synergistic effect of CH223191 and PP2 on AhR and AR activity, 
qRT-PCR was used to quantify mRNA expression of AhR responsive genes (AhR and 
CYP1B1) and AR responsive genes (AR and KLK3). Since AhR is constitutively active 
within the C4-2 cell line [25], CH223191 reduced AhR and CYP1B1 gene expression 
more than twofold when compared to the control. While PP2 alone also decreased AhR 
and CYP1B1 gene expression, inhibition of gene targets was further enhanced when the 




be very similar to the expression of AhR when treated with CH223191 and PP2 as well as 
when both drugs were used in combination. Elevated AhR and CYP1B1 gene expression 
reported before tumor formation in a rat model of mammary tumorigenesis suggested 
differential CYP1B1 regulation by a constitutively active AhR. CYP1B1 expression was 
diminished by repression of AhR activity [156]. Because of the fundamental role of 
androgens in prostate development as well as prostate cancer, our objective was to 
investigate if the effect of CH223191/ PP2 also affected gene expression of AR and 
downstream target gene KLK3 (PSA). 50 μMCH223191 reduced AR gene expression by 
60% in C4-2 cells. An identical decrease in AR expression was observed in response to 
treatment with PP2. These results helped to confirm that these drugs do not only decrease 
the expression of AhR but AR as well. Additionally, when C4-2 cells are co-treated with 
CH223191/PP2 AR expression is reduced by 85%. Furthermore, KLK3 which encodes 
for the glycoprotein prostate specific antigen (PSA) was observed to have a 65% and 
70% decreases in expression in the presence of CH223191 and PP2 respectively. Yet, 
when these two drugs were used in combination the level of KLK3 mRNA expression 
was decreased even further to more than 97%. Therefore, it can be concluded that these 
drugs have an inhibitory effect on AhR and AR even more so when used in combination 
(See Appendix Figure 18). 
Simultaneous reduction of AhR and Src signaling significantly reduces proliferation 
      While expression and activity data confirmed the effectiveness of combination 
therapy on AR, next we examined those effects on the growth of C4-2 cells. Asim et al. 




cell growth [21]. The influence of AhR and Src on androgen independent cell line growth 
was observed when C4-2 cells were grown for 24±72 hours in the presence and absence 
of CH223191 and PP2. There was no significant difference between the four treatments 
on the rate of growth after 24 hours exposure. Growth of C4-2 cells was significantly 
inhibited in the presence of CH223191 and PP2 at 48 and 72 hours. Furthermore, 
CH223191/PP2 demonstrated a synergistic effect on growth inhibition at 48±72 hours. 
After 72 hours of exposure to the combination, C4-2 cells exhibited a 50% decrease in 
overall growth rate compared to DMSO and compared to 25% when CH223191 or PP2 
were used alone. Together these finding show co-inhibition of AhR and Src 
synergistically reduce the growth rate of C4-2 PCa cells (See Appendix Figure 19). 
        Cell cycle analysis revealed an increase in the percent of cells in the G0/G1 phase of 
the cell cycle when cells were treated with either CH223191 or PP2. The percentage of 
cells remaining in G0/G1 was further increased when cells were co-treated with 
CH223191 and PP2 corresponding with the reduced growth rate seen with simultaneous 





 CHAPTER III  
MATERIALS AND METHODS 
 
 
Chemicals and Reagents 
G 418 disulfate salt was purchased from Sigma-Aldrich (St. Louis, MO). AhR antagonist, 
(CH223191) was purchased from Sigma Aldrich. Src kinase inhibitor, protein 
phosphatase 2 (PP2) was purchased from Sigma Aldrich. AR antagonist (Biclutamide) 
was purchased from Sigma-Aldrich. 
Prostate Cell line 
       The prostate cancer cell line LNCaP was purchased from American Type Culture 
Collection (ATCC). C4-2 human prostate cancer cell lines was a gift from Dr. Valerie 
Odero-Marah, Clark Atlanta University, Atlanta, GA. 
Transfection with PLNCX2 or AhR 
         AhR was stably overexpressed in LNCaP cells using AhR retroviral vector. Also, the 
LNCaP cells transfected with PLNCX2 was used as control cell line. We used G418 
sulfate for selection of AhR transfected cells. G418 is aminoglycoside antibiotic related 
to gentamycin that inhibits prokaryotic and eukaryotic protein synthesis. G418 is toxic to 






aminoglycoside 3'-phosphotransferase inactivates G418 by phosphorylation. Introduction 
of either of neor/kanr genes into cells can confer resistance to G418, which enables cells 
to grow in media containing G418. 
Subcloning DH5α Competent Cells 
           Subcloning DH5α competent cells are recommended for routine subcloning into 
plasmid vectors. The competent cells were thawed on ice, and 5 μl of each retroviral 
vector (AhR and PLNCX2 retro viral vector) were transformed into DH5α cells 
immediately following thawing. Cells were mixed by swirling following 30 minutes 
incubation on ice and 20 seconds heat shock in 42°C water bath and again 2 minutes 
incubation on ice. 950 μl pre warmed S.O.C. medium was added and cells were incubated 
at 37 °C for 1 hour at 225 rpm in environmental incubator shaker. Transformed cells (20 
and 50 μl) were added to agar plates and they were incubated at 37°C for 24 hours in a 
humidified, 5% CO2 atmosphere. After 24 hours, colonies were picked from streaked 
selective plates and starter culture of 3 ml of Luria broth with 100 μg/ml ampicillin was 
inoculated. They were incubated for 8 hours at 37 °C, 300 rpm in environmental 
incubator shaker. 
        For plasmid DNA purification, Qiagen Plasmid Mini Kit was used and pure DNA 
was isolated. A nano drop was used to read the DNA concentration and determined the 
yield.  
 Retrovirus packaging 
        Phoenix-E cells were transfected essentially. The day prior to transfection, 2 × 106 





following day the medium was replaced with medium containing 25 μM chloroquine 
(Sigma) for 5 to 10 min before the addition of the DNA-calcium phosphate 
coprecipitates. Then, 5 μg of each plasmid was mixed with 61 μl of 2 M CaCl2 (Sigma) 
and water to a final volume of 500 μl. This solution was added to 500 μl of HEPES-
buffered saline (50 mM HEPES, 10 mM KCl, 12 mM dextrose, 280 mM NaCl, 1.5 mM 
Na2HPO4; final pH, 7.05) and mixed by vigorous bubbling for 1 min. The resulting 
suspension was immediately added to the Phoenix-E cells, and the plate was gently 
rocked to achieve a uniform distribution of the precipitates. Cells were returned to the 
37°C incubator for 8 h. Then the medium was replaced with 4 ml of growth medium. The 
following day, the medium was changed to 3 ml of fresh medium every day, and the cells 
were incubated at 32°C for 24, 48, 72 hours before the supernatants were harvested each 
day. 
        One day prior to infection, LNCaP cells were plated in 12-well dishes at a density of 
5 × 104 cells/well. Cells were infected in a total volume of 0.5 ml containing 72h 
supernatant in the presence of 4 μg of Polybrene (Sigma) per ml. 16 hours later; 
supernatant was changed with fresh medium and incubated for 24 hours  before adding 
G418 sulfate( 300 μg/ml media)  for selection of AhR overexpressed cells.  
         After 7 days, the cells were collected and 50 cells were plated in 100 mm dishes as 
single cells. Some cells created clones which were isolated and plated in 12-well dishes. 







Cell Culture  
  Adherent monolayer cultures of LNCaP over expressed AhR (positive) and LNCaP 
empty vector (control) human prostate cancer cell lines were maintained in RPMI 1640 
medium supplemented with 10% FBS. Cells were grown at 37 ̊C with 5% CO2 in 
humidified atmosphere, and media was replaced every other day. Cells were split (1:3), 
when they reached near confluence.  
Cell Treatments 
        To determine the effects of AhR, Src kinase and androgen receptor inhibitor on 
LNCaP over expressed AhR and LNCaP empty vector human prostate cancer cell lines, 
we used 50 µM CH223, 30 µM PP2, 20 µM Bicalutamide for different time line.  
Subcellular Fractionation 
        Protein samples were isolated form LNCaP over expressed AhR and LNCaP empty 
vector human prostate cancer cell lines using the Thermo Scientific NE-PER Extraction 
kit for cellular fractions. The NE-PER Reagents efficiently solubilize and separate 
cytoplasmic and nuclear proteins into fractions with minimal cross-contamination or 
interference from genomic DNA and mRNA. 
Quantification of Total Proteins 
     Prostate cells were grown to confluence in 10 cm2 cell culture plates. Cells were 
washed with 5 ml of cold 1X phosphate buffer saline (PBS). The PBS was removed by 
vacuum aspiration. Cell lysis buffer was freshly prepared and 500 µl added to the cells. 
The cells were scraped and total cell lysate added to a 1.5 ml microcentrifuge tube. 





collected and stored at -80 ̊ C. The protein concentrations were determined by 
modified Lowery Assay method using the BioRad DC protein assay kit in accordance 
with manufacture`s instruction. Briefly, 150 µl of Reagent A ( an alkaline copper 
tartrate solution) was added to each total cell lysate sample ( 5 µl of total cell lysate 
in 25 µl of nanopure water) followed by the addition of 1.2 ml of Reagent B ( Folin 
Reagent) and allowed to incubate at room temperature. After 15 minutes, 
absorbance was read at 750nm. A standard curve was prepared each time the assay 
was performed using bovine serum albumin as a standard. 
Immunoprecipitation 
      LNCaP over expressed AhR and LNCaP empty vector human prostate cancer cell 
lines were lysed in lysis buffer. Total cell lysates containing 500 µg proteins were 
used for immunoprecipitation. Supernatants were precleared by centrifugation after 
1 hour of incubation at 4 ̊ C with 30 µl of immobilized protein-A Sepharose beads. 
The resulting supernatants were incubated with 5 µg of anti- AR antibody overnight 
at 4 ̊ C. Immunocomplexes were collected by centrifugation after incubation with 
protein A Sepharose beads and were analyzed by Western blot analysis with anti- 
Phospho AR anti body. 
Protein Isolation and Western Blot Analysis 
     Protein samples were isolated for cellular fractions (described above) and total protein 
lysates (were collected with cell lysis buffer (Cell Signaling)) were resolved by SDS-
PAGE and transferred to a PVDF membrane. Immunoblotting were carried out with 200 





AR monoclonal antibody at 1:50 dilution in 5% milk, 200 µg/ml rabbit pAR polyclonal 
antibody at 1:100 dilution in 5% BSA (Bovine Serum Albumin), 200 µg/ml mouse Src 
monoclonal antibody at 1:100 dilution in 5% milk, and 100 µg/ml rabbit pSrc 
monoclonal antibody at 1:1000 dilution in 5% BSA. Blots were washed three times (10 
min each) with Tris-buffered saline containing 0.2% Tween 20 (TBST). The blots were 
then incubated in 1:2500 dilution of secondary antibody and were washed three times (15 
min each) with Tris-Buffered Saline (TBS). Bands were visualized with the enhanced 
chemiluminescence (ECL) kit as specified by the manufacturer (GE Healthcare). 
Multiple exposures of each set of samples were produced. The relative concentration of 
target protein was determined by computer analysis using image J and normalized to an 
internal standard (topoisomerase, β-tubulin, and β-actin). 
RNA Extraction and Quantitative Real Time Polymerase Chain Reaction (qRT-
PCR) 
       Total RNA was isolated from cell monolayers grown on 100 mm tissue culture dishes 
using RNeasy Mini Kit (Qiagen). 2 µg of the total RNA was reverse-transcribed using the 
Superscript II kit (Invitrogen), according to the manufacturer’s recommendations. The 
cDNA served as a template in a 25 µl reaction mixture and was processed using the 
following protocol: an initial denaturation at 95°C for 3 min, followed by 39 
amplification cycles (95°C for 10 s and 55–65°C for 30 s), 95°C for 10 s, 65°C for 5 s 
and 95°C for 50 s. The 25 µl qPCR reaction mixture was mixed with GoTaq qPCR 
Master Mix (Promega). Melt curve analyses were performed after each run to ensure a 





method. The primer sequences used are in Appendix Table 1. Primers to amplify the 470-
bp cDNA fragment encoding L19 were used as an internal control. Gene expression was 
measured at least in triplicate for each sample and each quantification experiment was 
repeated three times starting with independent cell treatments and results were subjected 
to statistical analysis. 
 
XRE and ARE Promotor Activity 
      LNCaP overexpressed AhR and LNCaP empty vector ( 4 × 104 cells per well) were 
plated in a 96 well plate.  LNCaP overexpressed AhR and LNCaP empty vector human 
prostate cancer cell lines were transfected with XRE reporter and ARE reporter, as well 
as with positive and negative control reporter plasmids using attractene. After 16 hours of 
transfection, media were changed to standard assay media (DMEM +0.5% FBS +0.1 mM 
NEAA). Cells were grown for an additional 8 hours under normal cell conditions. After 
24 hours of transfection, a dual luciferase assay was performed, and promoter activity 
values expressed as arbitrary florescence units (AFU). Experiments were performed in 
triplicate and the standard error was indicated. 
Immunocytochemical Staining  
       LNCaP overexpressed AhR and LNCaP empty vector cells grown on glass cover 
slips in 6-well plates were washed in cold Phosphate Buffered Saline (PBS) and fixed by 
incubation in a 1:1 methanol: acetone solution at 4°C for 30 minutes and then air dried. 
Cells were rinsed and hydrated with Tris-buffered saline containing 0.05% Tween 20 





temperature for 1 hour in 5% milk solution in TBST to block nonspecific binding, 
followed by incubation at room temperature for 1 hour with affinity-purified rabbit anti-
AhR polyclonal antibody at 1 μg/ml at 1:1000 dilution in 4% milk solution in TBST and 
200 µg/ml mouse AR monoclonal antibody at 1:50 dilution in 4% milk solution in TBST. 
Cells were then washed three times (15 min each) with TBST. Cells were incubated with 
a 1:200 dilution of either fluorescein isothiocyanate (FITC)-conjugated anti-rabbit 
antibodies or tetramethyl rhodamine isothiocyanate (TRITC)-conjugated anti-mouse 
(Jackson Immunoresearch laboratories, West Grove, PA) in 4% milk at room temperature 
for 1 hour. The cells were washed three times (15 min each) with TBST, three times (10 
min each) with TBS and once with ddH20 (10 min).  Cells were mounted on slides using 
UltraCruz hard set mounting medium containing 4’6’-diamidino-2-phenylindole (DAPI).  
Proliferation Studies 
       LNCaP overexpressed AhR and LNCaP empty vector cells were resuspended to a 
final concentration of 1.0 × 105/mL in RPMI. 100 µl of the cell suspension (10,000 
cells) were added to each well of the 96-well plate. The micro plates were incubated at 
37°C for 24 hours in a humidified, 5% CO2 atmosphere. Per manufacturer’s instructions, 
following incubation, BrdU working stock had prepared by diluting the BrdU Label 
1:2000 into fresh tissue culture media.  20 µl of this working stock was added to each 
well.  BrdU was incubated with cells for 24 hours in the tissue culture incubator. 
Absorbances were read at 490 nm using the Synergy H1m multimode micro plate reader. 
       After removing contents of wells, 200 µl of the Fixative/Denaturing Solution was 





Antibody diluted in the Antibody Dilution Buffer. 100 µl of this solution was added to 
each well and incubated for 1 hour at room temperature. Wells were washed 3 times with 
automatic plate washer with 1X Wash Buffer. 100 µl of Peroxidase Goat Anti-Mouse 
IgG HRP Conjugate was added into each well and incubated for 30 min at room 
temperature.  After each wells was washed 3 times with 1X Wash Buffer, 100 µl of 
Substrate Solution was added to each well and incubated at room temperature for 15 min. 
100 µl of Stop Solution was added to each well in the same order as the previously added 
Substrate Solution. Absorbance was measured in each well using a spectrophotometric 
plate reader at dual wavelengths of 450-540 nm. 
Cell cycle profile analysis by flow cytometry 
       LNCaP overexpressed AhR and LNCaP empty vector human prostate cancer cell 
lines were grown in RPMI complete media. Cells were collected as a single cell in wash 
buffer, and fixed overnight in cold 100% ethanol. Fixed cells were washed with PBS+1% 
FBS, resuspended in PBS containing propidium iodide (40μg/ml) and 50μl of RNase A 
solution, Then incubated for 3 hours at 4°C and immediately analyzed by flow cytometry 
to obtain cell cycle profiles.  
In Vitro Cell Migration Assay  
       In vitro cell migration assay was performed using 24-well transwell pre coated 
inserts (8 µm).  The inserts were left for 2 hours at room temperature before being 
washed thoroughly with 3 ml RPMI. The cells were washed once with PBS and harvested 
from cell culture dishes by EDTA-trypsin into 50 ml conical tubes. The cells were 





RPMI supplemented with 10% FBS at the cell density of 5x105 cells /ml. 
Chemoattractant  solution were made by RPMI supplemented with 20% FBS. 500 µl of 
chemoattractant solutions were added into different wells of a 24-well plate. Aliquots of 
100 µl cell suspension were loaded into transwell inserts that were subsequently placed 
into the 24-well plate. The transwell insert-loaded plate was placed in a cell culture 
incubator for 5 hours. At the end of the incubation, transwell inserts were removed from 
the plate individually; the cells inside transwell inserts were removed by cotton swabs. 
The cleaned inserts were fixed in 300 µl of 4 % of paraformaldehyde (PH 7.5) for 20 
minutes at room temperature. Cells which had migrated to the outside of transwell 
inserted membrane were stained using DAPI staining kit. The stained cells are counted in 
five non-overlapping regions automatically by the microscope a microscope; the number 
of cells reflected the cell migration status in each transwell insert. The results were 
expressed as migration index defined as: the average number of cells per field for the 
medium control. The experiments were conducted at least three times using independent 
cell preparations. 
In Vitro Cell Invasion Assay  
       In vitro cell invasion assay was performed using 24-well transwell pre coated 
matrigel inserts (8 µm).  The inserts were left for 2 hours at room temperature before 
being washed thoroughly with 3 ml RPMI. The cells were washed once with PBS and 
harvested from cell culture dishes by EDTA-trypsin into 50 ml conical tubes. The cells 
were centrifuge at 500 x g for 10 minutes at room temperature; the pellets were 





Chemoattractant  solution were made by RPMI supplemented with 20% FBS. 500 µl of 
chemoattractant solutions were added into different wells of a 24-well plate. Aliquots of 
100 µl cell suspension were loaded into transwell inserts that were subsequently placed 
into the 24-well plate. The transwell insert-loaded plate was placed in a cell culture 
incubator for 48 hours. 5 minutes before the end of the incubation 300 µl ice-cold of 
3.7% paraformaldehyde was added to each wells and the wells were fixed with it. At the 
end of the incubation, transwell inserts were removed from the plate individually; the 
cells inside transwell inserts were removed by cotton swabs. Cells which had invaded to 
the outside of transwell inserted membrane were stained using DAPI staining kit. The 
stained cells are counted in five non-overlapping regions automatically by the 
microscope; the number of cells reflected the cell invasion status in each transwell insert. 
The results were expressed as invasion index defined as: the average number of cells per 
field for the medium control. The experiments were conducted at least three times using 
independent cell preparations. 
Statistical analysis 
        Each experiment was carried out in triplicate and all the values are expressed as 
mean +SEM. The differences between the groups were compared by t-test or ANOVA 
using Instant software (GraphPad Software Inc., San Diego, CA). A value of P<0.05 was 












4.1 Overexpression of AhR induces constitutive AhR signaling in LNCaP cells. 
4.1.1 Expression of AhR in different clones 
AhR protein and mRNA: AhR was stably overexpressed in LNCaP cells using 
AhR retroviral vector. Also, the LNCaP cells transfected with PLNCX2 was used as 
control cell line. Between multiple clones, we peaked up Clone A as moderate AhR 
overexpressed and Clone B as highly overexpressed AhR.  Total RNAs and proteins were 
extracted form LNCaP (PLNCX2, clone A, and clone B). The protein levels were 
determined by western blot analysis and the mRNA levels of AhR, CYP1A1 and 
CYP1B1 were determined by quantitative real time polymerase chain reaction. To 
examine the presence of AhR protein in these prostate cell lines, total cell lysate proteins 
were separated on 10% SDS-PAGE (Sodium Dodecyl Sulfate Polyacrylamide Gel 
Electrophoresis) and transferred on to PVDF membrane for western blot analysis with 
specific anti-AhR antibody. The western blot analysis revealed higher AhR protein 
expression in the clone A and B compare to the control (See Appendix Figure 21).  
Quantitative analysis showed that AhR protein was highly expressed in clone B, 
moderate expression in clone A, and weakly expressed in PLNCX2 cells (See Appendix 




the expression of AhR, CYP1A1 and CYP1B1, the levels of mRNA in the cell lines was 
determined using qRT-PCR. The results revealed, the highly overexpressed AhR cell 
line, clone B, showed further increase in gene expression for AhR and CYP1B1 
transcripts compare to clone A (a moderately overexpressed AhR clone) and the 
PLNCX2. Based on the results, gene expression in clone B is similar to C4-2 cell line and 
PLNCX2 is comparable to LNCaP cell line. For CYP1A1 transcript, the results show no 
significant change between the different cell lines.  
           AhR inhibitor effect on gene expression: To confirm that the increase of gene 
expression of CYP1B1 is based upon overexpression of AhR, we used 50 µM CH223 as 
AhR inhibitor on our cells. After 72 hours we extracted mRNA from all cell lines. The 
levels of mRNA in the cells was determined with qRT-PCR. As shown in appendix 
figure 23, when we used CH223 all cell lines showed significant decrease in CYP1B1 & 
AhR mRNA expression and it didn`t have effect on CYP1A1 mRNA expression.  
4.1.2 XRE promotor activity 
            LNCaP, PLNCX2, Clone A, Clone B and C4-2 cells were transfected with XRE 
reporter, as well as with positive and negative control reporter plasmids using attractene.  
The Cignal XRE luciferase reporter assays were utilized to determine the activity of AhR 
signaling pathways in all above prostate cancer cells in the presence and absence of AhR 
inhibitor. The assay showed that clone B has more promotor activity than clone A and 
control. It`s activity is comparable with C4-2 cell line (See Appendix Figure 24).  
CH223191 reduced AhR promoter activity by around 50 % in clone A& B and C4-2 cell 





4.2 Constitutive AhR signaling enhances Src kinase activity to functionally induce 
AR signaling. 
4.2.1 Overexpressed AhR increased AR, pAR and pSrc proteins & AR and it`s 
downstream target RNA expression  
         Protein and mRNA expression: We assessed the potential involvement of 
overexpressed AhR on other proteins and mRNA expression. We found that the AR, 
pAR, and pSrc protein expression levels markedly increased in the overexpressed AhR 
cell lines compare to PLNCX2. On the other hand, cSrc protein was expressed the same 
between all cell lines (See Appendix Figure 26). Furthermore, AR, KLK2 and KLK3 
mRNA expression were determined. The data demonstrated that AhR could induce 
upregulation of all targets in clone A moderately and highly in clone B compare to 
control (See Appendix Figure 27). 
           Src kinase inhibitor effect on gene expression: In our former result, CH223 
reduced AhR and CYP1B1 mRNA expression in LNCaP overexpressed cells. We 
explored the effect of PP2 in AR mRNA expression by determining the total mRNA 
levels of AR, KLK2 and KLK3. qRT-PCR analysis showed that the mRNA levels of all 
targets reduced in Clone A, B and C-2 cell lines. Total mRNA of all targets remained 
unchanged in PLNCX2 after exposing to PP2 (See Appendix Figure 28). Collectively, 
these results demonstrated that over expressed AhR induce its effect on AR via Src 
signaling pathway. 
4.2.2 ARE promotor activity 
      The Cignal ARE luciferase reporter assays were used to understand the activity of AR 




and absence of Src kinase inhibitor (PP2). The results demonstrated that we have increase 
in AR promotor activity in our clones comparable with C4-2. This increase in clone B is 
more than clone A (See Appendix Figure 29). Our data also showed that in the presence 
of PP2, AR promotor activity obviously decreased in clone A, B, and C4-2 cell lines, 
while it was unchanged in PLNCX2 and LNCap cells (See Appendix Figure 30)  
 
4.3 Constitutive AhR signaling induces castrate resistant phenotype 
4.3.1 Effect of bicalutamide on AR signaling & proliferation in LNCaP 
overexpressed cell lines 
         Bicalutamide effect on gene expression: AR antagonists compete with androgens 
for binding to the AR. In the androgen sensitive cell line like LNCaP when we use 
bicalutamide, it binds to androgen receptor and prevent androgen to bind to its receptor. 
We extended our studies to investigate whether bicalutamide has effect on AR gene 
expression in LNCaP overexpressed cell lines or not. Cells were treated with 
bicalutamide for 72 hours. Following this treatment, the level of AR, KLK2, and KLK3 
mRNA in the cell lines was determined using qRT-PCR. LNCaP and PLNCX2 cells 
showed significant reduction in all targets. The effect of bicalutamide on C4-2 and clones 
was different. As shown in Appendix Figure 31, this treatment didn’t have any effect on 
Clone A, B, and c4-2 in any targets. These results indicated that over expressed AhR cell 
lines are resistant to anti androgen therapy.  
      Effect of bicalutamide on overexpressed AhR cell lines proliferation: While expression 
and activity data confirmed the effectiveness of over expression AhR on AR, next we 




for 24-72 hours in the presence and absence of bicalutamide. There was significant 
difference between the clone A, B, C4-2 (as constitutive active AhR cell lines) and 
controls on the rate of growth after all time line exposure. We observed more growth rate 
for our clones and C4-2 cells in the absence of bicalutamide. We saw the most growth 
rate after 72 hours. Growth of LNCaP and PLNCX2 cells was significantly inhibited in 
the presence of bicalutamide at 72 hours. In contrast, there was no difference among 
proliferations in clone A, clone B, and C4-2 cells with or without bicalutamide at 24-72 
hours. Together these finding show with overexpressing AhR in LNCaP cell line we have 
significant increase in growth rate which is comparable with C4-2 as aggressive prostate 
cancer cell line. This growth increased didn’t response to anti androgen and this show 
that cells went to CRPC stage (See Appendix Figure 32). 
4.3.2 Overexpression of AhR promote G1 to S phase cell cycle transition 
      Flow cytometry method allows a precise analysis of the impact of various functional 
modulators on the cell cycle. DNA staining of viable cells followed by flow cytometry 
analysis and sorting provides an approach for selecting and recovering cells from various 
phases of the cell cycle. The duration of these cell cycle phases varies considerably in 
different kinds of cells.  Our cell cycle analysis revealed an increase in the percent of 
cells in the S phase of the cell cycle in LNCaP over expressed AhR. Percentage of the 
cells in S phase in clone B was 1.5 times more than clone A and in clone A is comparable 
with C4-2. The percentage of cells remaining in G0/G1 was increased in LNCaP and 






4.3.3 The effect of AhR overexpression on cell migration & invasion in LNCaP 
prostate cancer cells 
          Previous studies have shown that AhR expression was considerably higher in 
invasive and metastatic human cancer cells [16] and it has been suggested that AhR may 
be involved in the invasive and metastatic behavior of the cancer cells. To test this 
possibility, we performed migration and invasion assay for LNCaP over expressed AhR 
and PLNCX2, LNCaP, C4-2 (as controls). Our results showed that AhR over expression 
stimulated cell migration & invasion in clone B (high overexpressed AhR) more than 
Clone A (moderate overexpressed AhR). Also, we observed C4-2 as a positive control 
has more cell migration & invasion compare to LNCaP and PLNCX2 cell lines. Overall, 
AhR significantly induced cell migration and invasion in both genetically modified cell 
lines (clone A & B) and constitutively AhR active cell line (C4-2) (See Appendix Figure 







     The LNCaP cell line, derived from a lymph node metastasis, is a widely used human 
prostate cancer cell line used to demonstrate androgen sensitivity [157]. The LNCaP cells 
showed cytoplasmic AhR protein; however, they are virtually devoid of AhR expression 
in the nucleus. AhR regulates exogenous ligands in LNCaP cells for activation [25]. 
Therefore, we performed present study to show the effect of AhR overexpression in 
LNCaP cells. The results presented in this study demonstrated that with transfecting 
LNCaP cells with AhR we had overexpresses AhR protein in LNCaP cells. After we 
confirmed protein overexpression, our plan was verification of constitutive activity of this 
overexpression. As we know mRNA expression of CYP1B1, not CYP1A1, is regulated 
by constitutive AhR activity [156]. The mRNA expression level of AhR and CYP1B1 
proved that clone A had a modest increase in AhR and CYP1B1 expression and clone B 
had a significantly increase in both target. This transcriptional activity revealed that AhR 
was translocated to the nucleus. CYP1A1 mRNA expression remained unchanged despite 
the AhR overexpression which supports previous reports. Our results also confirmed 
more AhR promoter activity in our clones compare to controls.  
     We previously determined that AhR inhibitor CH223191 in concentrations of 50 µM 





transcriptional and promoter activity in new cell lines. Since CH223 decreased AhR 
transcriptional and promoter activity, it proved that those increase is the effect of AhR 
overexpression.  
      Increasing evidence suggest a role for AhR in the regulation of hormone signaling. 
AhR has been shown to have inhibitory as well as stimulatory-crosstalk with the estrogen 
and androgen receptor. The contradictory roles of AhR in androgen signaling have been 
contributed to cell specificity. However, the differences may be attributed to the receptor 
having distinct functions as a xenobiotic receptor that differs from its intrinsic functions 
[25]. There are numerous possible mechanisms for AhR and AR interaction.  For 
example AhR and androgen receptor share a number of coactivator proteins such as 
SRC1 and p300, Therefore, their interaction can happen via these coactivators [135]. The 
other possible mechanism is direct interaction between AhR and AR [25]. In addition AR 
has been shown to be activated by Src kinase mediates phosphorylation [21]. Activation 
of AhR enhances Src kinase activity and may serve as a mechanism of cross talk between 
AhR and AR signaling pathways. 
     Src shown to act as a regulator between intercellular and membrane proteins. Src 
activation, which has been reported in multiple types of cancers, can result in activation 
or repression of signaling pathways. [158-160]. Studies have also shown direct 
interaction between Src and AR. Src was shown to enhance the tumor progressive 
properties of AR in the absence of specific ligands to activate AR. In LNCaP prostate 
cancer cells, EGFR was shown to induce Src interaction with AR through the proline-rich 
region within the SH3 domain. This interaction resulted in Src activation and enhanced 




and Src interaction increased apoptosis in LNCaP tumor xenografts [161]. These reported 
actions of Src make it an ideal target for treatment of men with advance stages of prostate 
cancer [150]. However, monotherapy designed clinical trials using Src inhibitors have 
had limited success and combination therapy may prove more beneficial. Considering Src 
is an integral component of the cytosolic AhR complex, AhR activity may lead to 
persistent phosphorylation of AR by Src kinase even in the presence of Src inhibitors 
[136]. Coimmunoprecipitation experiments revealed that AhR forms a protein complex 
with Src and regulates activity by phosphorylating Src (Tyr416) and dephosphorylating 
Src (Tyr527) [17]. Immunoprecipitation assays revealed the association of AR with Src, 
suggesting complex formation among them [138]. Other studies have shown that Src 
kinase can cause AR transactivation in C4-2 PCa cells. In these studies, a specific Src 
kinase inhibitor resulted in decreased AR activation and invasion of C4-2 cells [21]. 
Previous evidence that Src can facilitate crosstalk between AhR and other transcription 
factors supports the premise that Src is capable of mediating crosstalk between AhR and 
AR. Src mediated crosstalk between AhR and epidermal growth factor receptor. The 
resulting crosstalk enhanced proliferation of colon cancer cells [17]. 
      The molecular mechanism of AhR and AR crosstalk needs to be investigated further 
and could be multifaceted. Based of know mechanism of AhR interactions, the receptor 
may induce activation of AR by direct heterodimerization and overlapping coactivators 
as well as protein phosphorylation [25]. Our findings in preliminary studies we did for 
this research indicate that co-inhibition of Src and AhR represses AR function in a 
synergistic manner. Co-inhibition of AhR and Src with CH223191 and PP2 respectively 




decreased AR transcriptional activity as evidenced by a significant decrease in the 
activity of an androgen responsive element luciferase assay and expression of androgen 
responsive genes. Consequently growth of CRPC cell line, C4-2, was significantly 
inhibited by co-targeting AhR and Src when compared to individual inhibition of both 
pathways. AR signaling is essential for the progression of prostate cancer. Simultaneous 
inhibition of AhR and Src could abolish AR signaling and decrease mortality associated 
with CRPC.  
      Although AhR signaling components have been investigated in cancer cells, only a 
few reports have shed light on its influence on invasiveness and metastatic potential [15]. 
In preliminary data we explained AhR role in CRPC cell line, C4-2. Based upon those 
results we performed other experiments to show AhR can induce CRPC phenotypes in 
androgen sensitive cell line (LNCaP). Our results exhibited over expression AhR in 
LNCaP cells is causing the constitutive activity of AhR and it can increase AR, pAR, 
pSrc protein expression level. Furthermore, we found constitutive AhR activity in LNCaP 
cell line regulates the transcriptional and promotor activity of androgen receptor. AR and 
its downstream target genes (KLK2, KLK3) mRNA expression pattern correlate with 
AhR mRNA expression level.  
       Androgens regulate numerous functions during normal development and in 
adulthood. AR is primarily responsible for mediating the physiological effects of 
androgens by binding to AREs. Several studies have shown the Src mediated 
phosphorylation of AR at Y534 resulting in transcriptional activation of AR in the 




AR signaling. The results further confirmed the transcriptional and promotor activity of 
androgen receptor in constitutive active AhR cell line was based upon Src kinase activity. 
      Although these results indicate that AhR employs Src to increase AR signaling some 
studies have identified TCDD, BaP, and 3-methylcholanthrene (3MC) repress androgen-
induced gene transcription and cell proliferation in human prostate cancer cells [163, 
164]. Cross-talk between AR and AhR mediated signal transduction pathways plays an 
important role in the inhibitory effects of TCDD.  Sanada et.al reported that DHT 
represses 3MC-induced transcription of CYP1A1, CYP1A2, CYP1B1, and AhRR genes 
in LNCaP cells, and their results suggest that complex formation between AR and AhR is 
important for repression of 3MC-induced gene transcription by DHT [165]. This 
conflicting results can be depending on cell types. All our results are in constitutive 
active AhR cell line and their results are in ligand dependent AhR activity cell lines.  
          One of the most fundamental questions concerning the role of the AhR in 
carcinogenesis is whether constitutive AhR signaling can induces castrate resistant 
phenotype. A number of studies have examined the role of the AhR in tumorigenesis and 
a complex story has emerged with reports that detail the ability of AhR activation to 
enhance or repress tumorigenesis [15]. As we know pharmacological inhibition of AR by 
bicalutamide (CDX) greatly decreases cell viability and tumor growth in prostate cancer 









 A growing number of studies have reported AhR promotes proliferation in the 
absence of exogenous ligands, whereas treatment with exogenous ligands inhibits cellular 
proliferation [170]. As we have briefly described earlier, the aryl hydrocarbon receptor 
pathway cross-talks with androgen receptor signaling pathway leads cells in directions of 
proliferation, cell cycle progression, or migration. In contrast, we have evidence for 
negative regulation with AR-AhR crosstalk. TCDD is an AhR ligand which stimulates 
CYP1A1 gene transcription and CYP1A1 enzymatic activity in LNCaP prostate cancer 
cells. Testosterone as an AR ligand can repress TCDD’s effect. The mechanism by which 
this occurs is not fully understood [171, 172]. To evaluate the AhR role in any type of 
tumor cell, we face lots of difficulty because of AhR’s ability to crosstalk with several 
signaling factors. Further processes, such as the transporter and metabolic activities of 
tumor cells, can regulate AhR responsiveness.  
    The metabolic activities of cancer cells may cause a reduction in the exposure to AhR 
ligands [173, 174]. Therefore, it seems likely that the AhR behavior in cancer is probably 
highly circumstantial, which may reason for the contradictory observations that AhR 
exhibits both tumorigenic and suppressor activity. Numerous forms of cross-talk between 
AR- and AhR facilitate signal transduction pathways have been described. The 




understanding of the function of AR and AhR in normal development and the toxicities 
of AhR agonists.  
      The present study was undertaken to gain further insight into the role of AhR on 
prostate cancer progression to castration resistant phenotype. Our study demonstrated that 
ectopic overexpression AhR in LNCaP prostate cancer cell line induced constitutive AhR 
activity. Next step was to determine the effect of this constitutive activity on AR 
signaling. There are several mechanisms for AR and AhR interaction. One possible 
mechanism is dependent on the Src kinase signaling pathway. AhR and Src were found to 
be in complex within the cytoplasm. Upon AhR activation, Src was released from AhR 
and went on to phosphorylate AR. Activated AR translocated to the nucleus and formed a 
homodimer with another phosphorylated AR. That homodimer bound to ARE 
subsequently induced transcriptional regulation of specific genes (See Appendix Figure 
36). Our results confirm this mechanism by demonstrating elevated levels of pSrc and 
pAR protein expression and AR promoter and transcriptional activity in our clones. 
Another possible mechanism is direct interaction between AhR and AR. We will perform 
co-IP assay in order to illustrate the presence of this interaction in our overexpressed 
LNCaP cell line.  
        We then sought to determine if all these impact LNCaP nature from androgen 
sensitive to androgen resistant. We observed biological effect that occurred during this 
process such as promotes cells from G1 to S phase and increasing proliferation, invasion, 
and migration. Moreover, we exposed clones to bicalutamide treatment. This did not 




     Hisamitsu groups recently published a paper which studied AhR overexpression in 
LNCaP cells. All outcomes they presented in their study derived from the data using a 
single cell line LNCaP [175]. We tried to overcome this problem by using C4-2 as 
positive control and LNCaP to monitor our PLNCX2 as control. Also, we performed two 
overexpressed LNCaP cell lines, one as moderate overexpression AhR and the other one 
as highly overexpressed AhR. Moreover, our research focused on the growth, 
invasiveness and effectiveness of specific inhibitory drug on each step. Moving forward, 
additional experiments, such as angiogenesis and epithelial mesenchymal transition, 
could be added for complementary results. In vivo studies might be considered in order to 
precisely determine the function of AhR signaling pathway on metastatic potential in the 
complex tumor microenvironment. However, it is clear from numerous lines of evidence 
that AhR does impact tumor cell proliferation through diverse and contradictory 
mechanisms, thus making AhR a theoretical target for suppression of tumor growth 
[166]. More studies are needed to enhance our knowledge of the intracellular 






Table 1. Primer sequences for quantitative PCR                                                        
Gene Primer Sequence (qRT-PCR) 
L-19 Forward (5′-3′)  TCCCAGGTTCAAGCGATTCTCCTT 
 
Reverse (5′-3′) TTGAGACCAGCCTGACCAACATGA 
CYP1B1 Forward (5′-3′)  TGCCTGTCACTATTCCTCATGCCA  
 
Reverse (5′-3′) TCTGCTGGTCAGGTCCTTGTTGAT 
AhR Forward (5′-3′)  TCCTTGGCTCTGAACTCAAGCTGT 
 
Reverse (5′-3′) GCTGTGGACAATTGAAAGGCACGA 
KLK2 Forward (5′-3′)  TTAAGTCCACCTCACGTTCTGGCA 
 
Reverse (5′-3′) TACACCTGTGTCTGCCCATTCCTT 
KLK3 Forward (5′-3′)  ACTTCAGTGTGTGGACCTCCATGT 
 
Reverse (5′-3′) AGCACACAGCATGAACTTGGTCAC 
AR Forward (5′-3′)  GAGCTAGCCGCTCCAGTGCT 
 
Reverse (5′-3′) CCTAACCAGGCGGGTCGTGG 
CYP1A1 Forward (5′-3′)  GTCATCTGTGCCATTTGCTTTG  
 






Figure 1                                                          
 
http://radiologyreview.tumblr.com/post/18446506375/prostate 
Figure 1. The Prostate zone anatomy. The prostate consists of four zones: Anterior 










Figure 2. A schematic diagram of normal and enlarged prostate. Normal 
prostate and benign prostatic hyperplasia (BPH), a normal prostate does not block the 
flow of urine from the bladder. An enlarged prostate presses on the bladder and urethra 








Figure 3. Different stages of prostate cancer. As prostate cancer progresses 
from Stage I to Stage IV, the cancer cells grow within the prostate, through the outer 














Figure 4. Schematic view of several mechanisms promote castration-
resistant prostate cancer. Mechanism for progression to Castration resistant 
prostate cancer. Amplification/over-expression of the AR, AR gene mutations, increase 
AR signal transduction through alterations in coactivators/corepressors, Crosstalk with 







Asian J Androl. 2010 Sep; 12(5): 639–657. 
Figure 5. Schematic structure of the androgen receptor (AR). The exons, 
three functional domains and the relative positions of the polyglutamine repeats (Gln22) 
and the polyglycine repeat (Gly24) in the N-terminus are labeled. The numbers above the 
domains indicate the amino acid residues. NTD, N-terminal domain; DBD, DNA-binding 
domain; LBD, ligand-binding domain. AF-1, AF-5, AF-2 are three known transactivation 
domains in the AR. The two zinc fingers are located in the DNA-binding domain and are 
crucial structures for AR to bind to AREs. Amino acids of the P- and D-boxes are 










Figure 6. Schematic structure of AhR Functional Domains. The AhR 
protein contains several critical domains. A common entity in a variety of transcription 
factors is the bHLH motif which is located in the N-terminal of the protein. Members of 
this motif have two functionally unique and extremely conserved domains. The basic-
region (b) aids in the binding of the transcription factor to DNA. The helix-loop-helix 
(HLH) region, assists protein-protein interactions. PAS-A and PAS-B (PAS domains), 
involved in AhR’s dimerization partner with the ARNT. The function of these domains is 
to support specific secondary interactions with other PAS domain containing proteins to 
stimulate the formation of heterozygous and homozygous protein complexes. PAS-B 
domain and several conserved residues have role in the ligand biding site.  Lastly, in the 










Figure 7. AhR & ARNT Interaction. Various exogenous ligands and endogenous 
ligands can bind to the chaperone-bound cytoplasmic AhR, thereby stimulating 
translocation to the nucleus, where the chaperones are exchanged for ARNT. The AhR–
ARNT dimer binds to a cognate xenobiotic response element (XRE) in cis to induce 








Oncogene(2004) 23, 7918–7927 
Figure 8. Schematic structure of Src. The Src molecule consists of an N-terminal 
myristoylation sequence (Myr) connected to the SH4 domain. Following a unique region 
are SH3 and SH2 domains. After that is a kinase domain which contains Tyr419, and 










Figure 9. Inactive and active form of Src.  Src has to change the position of its 
phosphorylated tyrosine in order to be activated. This causes a conformational change 
from an inactive (phosphorylated in Y530) to an active form (phosphorylated in Y419). 

















Figure 10. Src and androgen receptor can activate each other via direct 
physical interaction. (A) Multiple extracellular signals can activate Src. This active 
form of Src, which is phosphorylated on Y419, can phosphorylate AR at Y534, resulting 
in activation of AR. (B) On the other hand, following ligand bind to AR, direct physical 









Figure 11. Expression of AhR mRNA and protein in LNCaP and C4-2 
prostate cancer cell lines. (A) mRNA expression of AhR in LNCaP and C4-2 
prostate cancer cell lines. mRNA levels were normalized using L-19 which serves as an 
internal control. (B) Quantitative real-time PCR was performed to quantify the 
expression level of AhR. L-19 was used as an internal control. (*) denotes statistically 
significant differences between cell lines. (C) AhR protein level with using an anti-AhR 
antibody (1:1000 dilution). Anti-β-actin was used as a loading control. (*) denotes 








Figure 12. Constitutive AhR signaling in castration resistant C4-2 
prostate cancer cell lines. (A) Subcellular localization of AhR by 
immunocytochemical staining. (B) Subcellular localization of AhR by nuclear and 
cytoplasmic fractionation. (C) RT-PCR analysis of CYP1B1 mRNA expression. (D) 













Figure 13. Constitutive AhR signaling regulates androgen receptor 
expression and activity. (A) Subcellular localization of AR in scrambled control 
(SCR) and AhR depleted (-AhR) C4-2 cells by immunocytochemical staining. (B) 
Subcellular localization of AR in C4-2 SCR and -AhR cells by nuclear and cytoplasmic 
fractionation. (C) Comparison of AR and phosphorylated androgen receptor (p-AR) 
protein expression in C4-2 SCR and -AhR by Western blotting. (D) RT-PCR analysis of 
androgen responsive genes mRNA expression in control (SCR) and AhR depleted (-AhR) 
clones. (E) Quantitative real-time PCR was performed to quantify the expression level of 









Figure 14. Constitutive AhR signaling regulates Src kinase expression 
and activity. C4-2 cells were transfected with a vector carrying a shRNA for AhR (-
AhR) or a scrambled control vector (SCR). Total cellular proteins were isolated from 
75% confluent cell cultures and separated by SDS polyacrylamine gel electrophoresis and 
blotted using anti-AhR antibody, anti-cSrc antibody, anti-pSrc antibody. Anti-β-actin 














Figure 15. AhR and Src inhibition synergistically reduces pAR 
expression. Parental C4-2 prostate cancer cells were also treated with AhR inhibitor 
(CH223191) and Src kinase inhibitor (PP2) alone and in combination. DMSO served as a 
vehicle control. Total cellular proteins were isolated and proteins were separated by SDS 
polyacrylamine gel electrophoresis and blotted using anti-AhR antibody, anti-AR 
antibody, anti-pAR antibody, anti-cSrc antibody, anti-pSrc antibody. Anti-β-actin was 














Figure 16. AhR and Src inhibition synergistically reduces AR nuclear 
localization. C4-2 cells grown on 100 mm dishes until 75% confluent was treated with 
DMSO, CH223191 and PP2 as described above. Cells were washed with cold PBS and 
cellular fractions were isolated per manufactures instructions using a NE-PER Extraction 
kit. The nuclear and cytoplasmic fractions were analyzed by western blotting for AhR 
and AR protein expression. The relative levels of cytoplasmic AhR & AR were 
normalized with β-tubulin expression and the relative levels of nuclear AhR &AR were 










Figure 17.  Simultaneous inhibition of AhR and Src significantly 
decrease AR and AhR promoter activity. C4-2 cells were transfected with an 
XRE reporter plasmid & ARE reporter plasmid, as well as with positive and negative 
control reporter plasmids using attractene. Following transfection, treatments were added 
to each appropriate plate. A dual luciferase assay was performed and promoter activity 
values are expressed as arbitrary florescence units (AFU). Each bar represents mean ± 
SEM (n = 3) and were analyzed by student t-test. (*) denotes statistically significant 




















Figure 18.  AhR and AR transcriptional activity synergistically ablated 
by CH223191 and PP2. qRT-PCR analysis examined AhR, CYP1B1, CYP1A1, AR, 
KLK2 and KLK3 mRNA expression in C4-2 prostate cancer cells. Cells were treated 
with 50 μM of AhR inhibitor (CH223191) or 30 μM of Src inhibitor (PP2) alone or in 
combination or with vehicle control (DMSO) for 72 h and total RNAs were isolated and 
quantitative RT-PCR was performed to determine the mRNA expression of each target in 
treated cells. mRNA levels were normalized using L-19 which serves as an internal 
control. Each bar represents mean±SEM (n = 3) and were analyzed by student t-test. (*) 










Figure 19. CH223191 and PP2 have a synergistic effect on proliferation 
of C4-2 prostate cancer cells.  Cells were grown in 96 well plates at 5.0 x 103 cells 
per well. The cells were treated with DMSO or 50 μM of CH223191 or 30 μM of PP2 
alone or in combination for 24±72 hrs. (A) Cell growth was measured using Promega 
CellTiter 96 Cell Proliferation Assay per manufactures instructions. Each bar represents 















Figure 20. CH223191 and PP2 have a synergistic effect on inhibiting S 
phase transition in C4-2 prostate cancer cells.  The cells were plated at a 
density of 1x106 cells/dish and exposed to DMSO or 50 μM of CH223191 or 30 μM of 
PP2 alone or in combination for 72 hrs. Cells were harvested and analyzed for cell cycle. 
The cells with DMSO exposure served as control. Bar graphs represent mean ± SD of 


























































Figure 21: Elevated AhR protein levels as a result of AhR 
overexpression in LNCaP cell line. Total cellular proteins were isolated and 
proteins were separated by SDS polyacrylamine gel electrophoresis and blotted using 
anti-AhR antibody. Anti-β-actin was used as a loading control. Figure is representative 























Figure 22. Overexpression of AhR leads to increased AhR 
transcriptional activity. qRT-PCR analysis examined AhR, CYP1B1, and CYP1A1 
mRNA expression in prostate cancer cells. Total RNAs were isolated and quantitative 
RT-PCR was performed to determine the mRNA expression of each target in cells. 
mRNA levels were normalized using L-19 which serves as an internal control. Each bar 
represents mean±SEM (n = 3) and were analyzed by student t-test. (*) denotes 




































































































































Figure 23. CH223191 reduced AhR transcriptional activity in AhR 
overexpressed clones. qRT-PCR analysis examined AhR, CYP1B1, and CYP1A1 
mRNA expression in prostate cancer cells. Cells were treated with 50 μM of AhR 
inhibitor (CH223191) or with vehicle control (DMSO) for 72 h and total RNAs were 
isolated and quantitative RT-PCR was performed to determine the mRNA expression of 
each target in treated cells. mRNA levels were normalized using L-19 which serves as an 
internal control. Each bar represents mean±SEM (n = 3) and were analyzed by student t-







Figure 24. Overexpression of AhR enhanced promoter activity in 
overexpressed AhR clones. Prostate cancer cells were transfected with an XRE 
reporter plasmid, as well as with positive and negative control reporter plasmids using 
attractene. Following transfection, a dual luciferase assay was performed and promoter 
activity values are expressed as arbitrary florescence units (AFU). Each bar represents 
mean ± SEM (n = 3) and were analyzed by student t-test. (*) denotes statistically 











Figure 25. CH223191 inhibits AhR promoter activity in overexpressed 
LNCaP cell line. Prostate cancer cells were transfected with an XRE reporter plasmid, 
as well as with positive and negative control reporter plasmids using attractene. 
Following transfection, Cells were treated with 50 μM of AhR inhibitor (CH223191) or 
with vehicle control (DMSO) for 18 h. A dual luciferase assay was performed and 
promoter activity values are expressed as arbitrary florescence units (AFU). Each bar 
represents mean ± SEM (n = 3) and were analyzed by student t-test. (*) denotes 























































































Figure 26. Overexpression of AhR enhances pSrc & pAR protein 
expression in overexpressed AhR clones. Total cellular proteins were isolated 
and proteins were separated by SDS polyacrylamine gel electrophoresis and blotted using 
anti-AhR antibody, anti-AR antibody, anti-pAR antibody, anti-cSrc antibody, anti-pSrc 
antibody. Anti-β-actin was used as a loading control. Figure is representative of 3 























Figure 27. AR transcriptional activity enhanced in clones 
overexpressing AhR. qRT-PCR analysis examined AR, KLK2 and KLK3 mRNA 
expression in prostate cancer cells. Total RNAs were isolated and quantitative RT-PCR 
was performed to determine the mRNA expression of each target in cells. mRNA levels 
were normalized using L-19 which serves as an internal control. Each bar represents 
mean±SEM (n = 3) and were analyzed by student t-test. (*) denotes statistically 
























Figure 28. PP2 down-regulated AR transcriptional activity in 
overexpressed AhR clones. qRT-PCR analysis examined AR, KLK2 and KLK3 
mRNA expression in prostate cancer cells. Cells were treated with 30 μM of Src 
inhibitor (PP2) or with vehicle control (DMSO) for 72 h and total RNAs were isolated 
and quantitative RT-PCR was performed to determine the mRNA expression of each 
target in treated cells. mRNA levels were normalized using L-19 which serves as an 
internal control. Each bar represents mean±SEM (n = 3) and were analyzed by student t-








Figure 29. Elevated AhR levels stimulates AR promoter activity in 
overexpressed AhR clones. Prostate cancer cells were transfected with an ARE 
reporter plasmid, as well as with positive and negative control reporter plasmids using 
attractene. Following transfection, a dual luciferase assay was performed and promoter 
activity values are expressed as arbitrary florescence units (AFU). Each bar represents 
mean ± SEM (n = 3) and were analyzed by student t-test. (*) denotes statistically 









Figure 30. PP2 inhibits AR promoter activity in overexpressed AhR cell 
lines. Prostate cancer cells were transfected with an XRE reporter plasmid, as well as 
with positive and negative control reporter plasmids using attractene. Following 
transfection, Cells were treated with 30 μM of Src inhibitor (PP2) or with vehicle 
control (DMSO) for 18 h. A dual luciferase assay was performed and promoter activity 
values are expressed as arbitrary florescence units (AFU). Each bar represents mean ± 






















Figure 31. CDX has no effect in AR transcriptional activity of 
overexpressed AhR clones. qRT-PCR analysis examined AR, KLK2 and KLK3 
mRNA expression in prostate cancer cells. Cells were treated with 20 μM of AR 
inhibitor (CDX) or with vehicle control (DMSO) for 72 h and total RNAs were isolated 
and quantitative RT-PCR was performed to determine the mRNA expression of each 
target in treated cells. mRNA levels were normalized using L-19 which serves as an 
internal control. Each bar represents mean±SEM (n = 3) and were analyzed by student t-








Figure 32. Proliferation of LNCaP over expressed AhR prostate cancer 
cells was unaltered following CDX treatment. Cells were grown in 96 well 
plates at  1.0 × 105 cells per well. The cells were treated with DMSO or 20 μM of CDX 
for 24-72 hrs. Cell growth was measured using Brdu Assay per manufactures 
instructions. The cells with DMSO exposure served as control. Bar graphs represent 
mean ± SD of three separate experiments, (*p <.05). 
  








Figure 33. Over expression of AhR promotes G1 to S phase cell cycle 
transition in clones. The cells were plated at a density of 1x106 cells and incubated 
for 72 hrs. Cells were harvested and analyzed for cell cycle. Bar graphs represent mean 
± SD of three separate experiments. 
  

















Figure 34. Overexpression of AhR significantly increases migration in 
clones. Migration of LNCaP over expressed AhR. C4-2 cultured alone served as 
positive controls and LNCaP as second control. Immunofluorescence expressions 
exhibited a blue-stained nucleus after 5 hours incubation. Bar graphs represent mean ± 





















Figure 35. Overexpression of AhR significantly increases invasion in 
clones. Invasion of LNCaP over expressed AhR. C4-2 cultured alone served as positive 
controls and LNCaP as second control. Immunofluorescence expressions exhibited a 































Figure 36. Proposal model of the effect of overexpressed AhR signaling 
in prostate cancer cells. Both TCDD, a ligand inducing AhR activity, and 
overexpression of AhR in the cell may cause the activation and release of Src from the 
AhR/Src complex. Then this activated Src can phosphorylate AR. Following this 
activation AR is able to translocate to the nucleus and homodimerizes. This AR/AR 
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